RANDOMIZED TRIAL OF BREAST SELF EXAMINATION IN SHANGHAI

描述：(改编自申请人摘要)。此应用程序 请求继续支持一项随机试验的最后五年 目前在上海纺织的435家工厂进行了BSE 工业局。这项研究的目的是确定 定期进行疯牛病治疗将降低乳腺癌的死亡率。完毕 年，267,000名年龄在30岁至之间的现役和退休女工 1989人按工厂随机分为干预组或对照组。女人 在1989-91年接受初步BSE指导的干预组中， 1991-92和1993-95年度的强化会议，以及多次临时会议 提醒他们从事疯牛病，并让医务人员监督他们的疯牛病 一年两次。所有女性都受到了积极关注，以获得生命地位和 在上海居住，并采用多种主动和被动方法 以确定所有发生的和致命的乳腺癌。高水平的 头五年的BSE合规性和执业能力 审判已被记录在案，也有能力跟踪高比例 并确定几乎所有乳腺癌死亡病例。AS 从乳房X光检查试验结果预计，乳腺癌死亡率 在两个研究小组的第四年(1994年)的随访率是相似的， 和最初一样，跟踪10年(到2000年) 预计的，将是必要的，并在此续期申请中建议。 没有提出进一步的干预活动。在经历了10年的 后续行动，将累积超过260万妇女年，这项试验 将有80%的检测能力将乳腺癌死亡率降低30%。

DESCRIPTION: (Adapted from Applicant's Abstract). This application requests continued support for the final five years of a randomized trial of BSE currently being conducted in 435 factories of the Shanghai Textile Industry Bureau. The purpose of the study is to determine whether the regular practice of BSE will reduce mortality from breast cancer. Over 267,000 current and retired female workers between the ages of 30 and 64 in 1989 were randomized by factory to an intervention or control group. Women in the intervention group received initial BSE instruction in 1989-91, reinforcement sessions in 1991-92 and 1993-95, and multiple interim reminders to practice BSE, and had their BSE supervised by a medical worker twice a year. All women are being actively followed for vital status and residence in Shanghai, and multiple active and passive methods are utilized to identify all incident and fatal breast cancers. High levels of compliance and competency in practicing BSE for the first five years of the trial have been documented, as has the capacity to track a high proportion of women in the study and identify virtually all breast cancer deaths. As anticipated from results of mammography trials, breast cancer mortality rates through year 4 of follow-up (1994) were similar in the two study arms, and follow-up for 10 years (through the year 2000), as originally anticipated, will be necessary, and is proposed in this renewal application. No further intervention activities are proposed. After 10 years of follow-up, over 2.6 million woman-years will have accrued, and this trial will have 80% power to detect a reduction in breast cancer mortality of 30%.